Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis
George Dimopoulos1, Dimitrios K Matthaiou, Drosos E Karageorgopoulos
1Alfa Institute of Biomedical Sciences (AIBS), Athens, GreeceDepartment of Critical Care, Attikon University Hospital, University of Athens, Athens, Greece.
Background:
The evidence for traditionally recommended 7- to 14-day duration of antibacterial therapy for community-acquired pneumonia (CAP) is not well established.
Objectives:
We endeavoured to assess the effectiveness and safety of shorter than traditionally recommended antibacterial therapy for CAP.
Methods:
We performed a meta-analysis of randomized controlled trials (RCTs) comparing short- (< or = 7 days) versus long- (> or = 2 days difference) course therapy for CAP with the same antibacterial regimens, in the same daily dosages.
Results:
Five RCTs involving adults (including outpatients and inpatients who did not require intensive care) and two RCTs involving children (aged 2-59 months, residing in developing countries) were included. All RCTs were double-blind and assessed patients with CAP of mild to moderate severity. No differences were found between short- (adults 3-7 days; children 3 days) and long- (adults 7-10 days; children 5 days) course regimens (adults - amoxicillin, cefuroxime, ceftriaxone, telithromycin and gemifloxacin; children - amoxicillin) regarding clinical success at end-of-therapy (six RCTs; 5107 patients [1095 adults, 4012 children]; fixed-effect model [FEM]; odds ratio [OR] = 0.89; 95% CI 0.74, 1.07), clinical success at late follow-up, microbiological success, relapses, mortality (seven RCTs; 5438 patients; FEM; OR = 0.57; 95% CI 0.23, 1.43), adverse events (five RCTs; 3214 patients; FEM; OR = 0. 90; 95% CI 0.72, 1.13) or withdrawals as a result of adverse events. No differences were found in subset analyses of adults or children, and of patients treated with no more than 5-day short-course regimens versus at least 7-day long-course regimens.
Conclusion:
No difference was found in the effectiveness and safety of short- versus long-course antimicrobial treatment of adult and paediatric patients with CAP of mild to moderate severity.
Insights
Shorter antibacterial therapy durations for community-acquired pneumonia (CAP) are as effective and safe as longer courses. This meta-analysis found no significant differences in clinical success, mortality, or adverse events for shorter treatment regimens in adults and children with mild to moderate CAP.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- The optimal duration of antibacterial therapy for community-acquired pneumonia (CAP) remains uncertain, with traditional recommendations lacking robust evidence.
- Current guidelines often suggest 7- to 14-day treatment courses for CAP.
Purpose of the Study:
- To evaluate the effectiveness and safety of shorter antibacterial therapy durations compared to traditional longer courses for CAP.
- To synthesize evidence from randomized controlled trials (RCTs) to inform clinical practice regarding CAP treatment length.
Main Methods:
- A meta-analysis of double-blind randomized controlled trials (RCTs) was conducted.
- Included RCTs compared short (< or = 7 days) versus long (> or = 2 days difference) antibacterial therapy courses for mild to moderate CAP in adults and children.
- Data on clinical success, microbiological success, relapses, mortality, and adverse events were analyzed.
Main Results:
- No significant differences were observed between short-course (adults 3-7 days; children 3 days) and long-course (adults 7-10 days; children 5 days) regimens in terms of clinical success, microbiological success, relapses, mortality, or adverse events.
- Analysis included 5107 patients (1095 adults, 4012 children) across seven RCTs.
- Subset analyses confirmed no differences in effectiveness or safety between treatment groups.
Conclusions:
- Short-course antibacterial treatment is as effective and safe as long-course treatment for mild to moderate community-acquired pneumonia in both adult and pediatric populations.
- These findings challenge traditional treatment duration recommendations and support the use of shorter antibiotic courses for CAP.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:14Atypical Pneumonia
01:25Clinical Significance of Antibiotic Resistance
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care